

APPENDIX A

SEQUENCE LISTING

<110> Eclagen Limited

<120> Improvements in or Relating to Peptide Delivery

<130> Improvements in or relating to peptide

<140>

<141>

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 1

gcagccgcga agtatatctg caactcatcc tgcgatg

36

<210> 2

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 2

catgcaggat gagttgcaga tataacttcgc ggctgc

36

<210> 3

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 3

gcagccgcgg gaataactagg gttcgtattt acacta

36

<210> 4

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 4

tagtgtaaat acgaacccta gtattcccgc ggctgc

36

<210> 5

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 5

ggccgctacg gacgaaagaa gaggcgtcaa cgacgcagac ca

42

<210> 6

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 6

tggtctgcgt cgttgacgcc tcttctttcg tccgtagcgg cc

42

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 7

Lys Tyr Ile Cys Asn Ser Ser Cys Met

1

5

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 8

Gly Ile Leu Gly Phe Val Phe Thr Leu

1

5